BR0210744A - Combinação farmacêutica sinergìstica para a prevenção ou tratamento de diabetes - Google Patents

Combinação farmacêutica sinergìstica para a prevenção ou tratamento de diabetes

Info

Publication number
BR0210744A
BR0210744A BR0210744-9A BR0210744A BR0210744A BR 0210744 A BR0210744 A BR 0210744A BR 0210744 A BR0210744 A BR 0210744A BR 0210744 A BR0210744 A BR 0210744A
Authority
BR
Brazil
Prior art keywords
prevention
treatment
pharmaceutical combination
diabetes
synergistically
Prior art date
Application number
BR0210744-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Zoltan Szilvassy
Gyoergy Rabloczky
Peter Literati Nagy
Original Assignee
N Gene Res Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0102982A external-priority patent/HU0102982D0/hu
Priority claimed from HU0202204A external-priority patent/HU226244B1/hu
Application filed by N Gene Res Lab Inc filed Critical N Gene Res Lab Inc
Publication of BR0210744A publication Critical patent/BR0210744A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyridine Compounds (AREA)
BR0210744-9A 2001-07-17 2002-07-10 Combinação farmacêutica sinergìstica para a prevenção ou tratamento de diabetes BR0210744A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0102982A HU0102982D0 (en) 2001-07-17 2001-07-17 Synergic pharmaceutical composition
HU0202204A HU226244B1 (hu) 2002-07-05 2002-07-05 Gyógyszer-kombináció a diabétesz megelõzésére vagy kezelésére
PCT/HU2002/000067 WO2003007951A1 (en) 2001-07-17 2002-07-10 A synergistic pharmaceutical combination for the prevention or treatment of diabetes

Publications (1)

Publication Number Publication Date
BR0210744A true BR0210744A (pt) 2004-07-20

Family

ID=89980599

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210744-9A BR0210744A (pt) 2001-07-17 2002-07-10 Combinação farmacêutica sinergìstica para a prevenção ou tratamento de diabetes

Country Status (21)

Country Link
US (2) US7635674B2 (https=)
EP (1) EP1408966B1 (https=)
JP (1) JP4598390B2 (https=)
KR (1) KR100920560B1 (https=)
CN (1) CN1270713C (https=)
AT (1) ATE386523T1 (https=)
AU (1) AU2002354884B2 (https=)
BR (1) BR0210744A (https=)
CA (2) CA2682251A1 (https=)
CY (1) CY1107939T1 (https=)
DE (1) DE60225143T2 (https=)
DK (1) DK1408966T3 (https=)
ES (1) ES2300460T3 (https=)
IL (2) IL159412A0 (https=)
MX (1) MXPA04000324A (https=)
NO (1) NO20040153L (https=)
NZ (1) NZ531155A (https=)
PL (1) PL205826B1 (https=)
PT (1) PT1408966E (https=)
RU (1) RU2311907C2 (https=)
WO (1) WO2003007951A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044531A2 (en) * 2004-10-13 2006-04-27 Isis Parmaceuticals, Inc. Antisense modulation of ptp1b expression
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
US7763601B2 (en) * 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
ES2355680T3 (es) * 2006-11-02 2011-03-30 N-Gene Research Laboratories Inc. Reducción del sobrepeso o de la obesidad.
ZA200902761B (en) * 2006-11-02 2010-07-28 N Gene Res Lab Inc A pharmaceutical composition having antipsychotic, antidepressant or antiepileptic activity with reduced side effect
US20080208328A1 (en) * 2007-02-23 2008-08-28 Endovalve, Inc. Systems and Methods For Placement of Valve Prosthesis System
CN101801351B (zh) 2007-07-19 2012-12-12 武田药品工业株式会社 包含阿格列汀和盐酸二甲双胍的固体制剂
PT2868315T (pt) * 2007-12-04 2017-09-04 Remedy Pharmaceuticals Inc Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
US20090281143A1 (en) * 2007-12-10 2009-11-12 N-Gene Research Laboratories, Inc. Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity
WO2012142458A1 (en) 2011-04-13 2012-10-18 Isis Pharmaceuticals, Inc. Antisense modulation of ptp1b expression
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
CN105476995A (zh) * 2015-12-23 2016-04-13 青岛海之源智能技术有限公司 一种二甲双胍阿昔莫司复方缓释胶囊及制备方法
KR102642823B1 (ko) 2017-06-30 2024-03-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 모발 성장을 조절하기 위한 조성물 및 방법
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
CN115916202A (zh) * 2020-05-27 2023-04-04 科赛普特治疗学股份有限公司 糖皮质激素受体调节剂瑞拉可兰和cyp2c9底物的并行给药
EP4172159A4 (en) 2020-06-30 2024-01-10 The Regents of the University of California Compositions and methods for modulating hair growth

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6121278A (en) * 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
AU5296799A (en) * 1998-08-03 2000-02-28 N-Gene Kutato Kft. Pharmaceutical compositions against autoimmune diseases
UA65635C2 (uk) * 1998-09-03 2004-04-15 Н-Гене Кутато Кфт. НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ

Also Published As

Publication number Publication date
DE60225143T2 (de) 2009-02-12
IL159412A (en) 2009-09-22
RU2311907C2 (ru) 2007-12-10
EP1408966A1 (en) 2004-04-21
JP4598390B2 (ja) 2010-12-15
AU2002354884A2 (en) 2003-03-03
US20100048627A1 (en) 2010-02-25
ATE386523T1 (de) 2008-03-15
US20070015687A1 (en) 2007-01-18
MXPA04000324A (es) 2004-07-23
CN1531433A (zh) 2004-09-22
PL205826B1 (pl) 2010-05-31
KR100920560B1 (ko) 2009-10-08
DE60225143D1 (de) 2008-04-03
CA2682251A1 (en) 2003-01-30
IL159412A0 (en) 2004-06-01
CA2452558A1 (en) 2003-01-30
PT1408966E (pt) 2008-05-02
ES2300460T3 (es) 2008-06-16
PL364662A1 (en) 2004-12-13
EP1408966B1 (en) 2008-02-20
US7635674B2 (en) 2009-12-22
JP2004537550A (ja) 2004-12-16
RU2004105149A (ru) 2005-04-20
DK1408966T3 (da) 2008-06-16
US8048873B2 (en) 2011-11-01
KR20040029371A (ko) 2004-04-06
NZ531155A (en) 2005-07-29
CY1107939T1 (el) 2013-09-04
CN1270713C (zh) 2006-08-23
WO2003007951A1 (en) 2003-01-30
NO20040153L (no) 2004-03-16
CA2452558C (en) 2009-12-22
AU2002354884B2 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
BR0210744A (pt) Combinação farmacêutica sinergìstica para a prevenção ou tratamento de diabetes
BR9810312A (pt) Composição farmacêutica que apresenta atividade antitumoral acentuada e/ou efeitos colaterais reduzidos contendo um agente antitumoral e um derivado do ácido hidroxìmico
BR0310006A (pt) Derivados de 5-tio-beta-d-glicopiranosìdeo de arila e agentes terapêuticos para diabetes contendo os mesmos
AR035533A1 (es) Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
BR0213079A (pt) Forma de dosagem para o tratamento da diabetes mellitus
EP2263667A3 (en) Compositions comprising crystalline trans-(+/-)-delta-9-tetrahydrocannabinol
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
BR9911073A (pt) Uso de uma composição compreendendo formoterol e budesonida para a prevenção ou tratamento de uma condição aguda de asma
BR0109912A (pt) Novas combinações antelmìnticas
BR0209327A (pt) Composição para tratamento de constipação induzida por drogas
BR9712141A (pt) Aplicação de 1-hifróxi-2-piridonas para tratamento de infecções cutâneas.
BRPI9509819B8 (pt) benzamida enterocinética e composição farmacêutica compreendendo a mesma
BRPI0414518A (pt) composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e hormÈnio paratireoidiano
BR9912816A (pt) Composição terapêutica à base de flavonóides, tencionada para uso no tratamento de tumores por agentes citotóxicos
BR9807444A (pt) Produto antimicrobial
BR0212744A (pt) Formulações de cisplatina de toxicidade reduzida e métodos para uso das mesmas
ES2147796T3 (es) Composicion para el tratamiento o la prevencion del herpes.
BR0214487A (pt) Composição farmacêutica que compreende uma combinação de metformina e um ácido 4-oxobutanóico, e o uso da mesma para o tratamento de diabetes
BR0210063A (pt) Composição estável e uso da mesma
EP1362593A4 (en) PHARMACEUTICAL COMPOSITION AGAINST DIABETIC NEUROPATHY
ES2144452T3 (es) Medicamento para el tratamiento de infecciones protozoarias provocadas por babesia.
AU5284999A (en) New injectable formulations containing ramoplanin
WO2003043632A3 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
AU4519189A (en) Medicaments for the treatment of toxoplasmosis
AU4519289A (en) Medicament for the treatment of cryptosporidiosis

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]